Calamos Wealth Management Cut By $1.70 Million Its Facebook (FB) Position; Infinity Pharmaceuticals (INFI)’s Sentiment Is 1.22

Facebook, Inc. (NASDAQ:FB) Logo

Infinity Pharmaceuticals Inc (INFI) investors sentiment increased to 1.22 in 2018 Q4. It’s up 0.13, from 1.09 in 2018Q3. The ratio is better, as 28 active investment managers opened new and increased positions, while 23 sold and reduced holdings in Infinity Pharmaceuticals Inc. The active investment managers in our database now have: 30.65 million shares, up from 29.50 million shares in 2018Q3. Also, the number of active investment managers holding Infinity Pharmaceuticals Inc in top ten positions decreased from 1 to 0 for a decrease of 1. Sold All: 11 Reduced: 12 Increased: 14 New Position: 14.

Calamos Wealth Management Llc decreased Facebook Inc (FB) stake by 15.8% reported in 2018Q4 SEC filing. Calamos Wealth Management Llc sold 12,997 shares as Facebook Inc (FB)’s stock rose 22.38%. The Calamos Wealth Management Llc holds 69,266 shares with $9.08 million value, down from 82,263 last quarter. Facebook Inc now has $510.07 billion valuation. The stock decreased 0.14% or $0.25 during the last trading session, reaching $178.62. About 6.00 million shares traded. Facebook, Inc. (NASDAQ:FB) has declined 4.87% since April 17, 2018 and is downtrending. It has underperformed by 9.24% the S&P500. Some Historical FB News: 23/04/2018 – Investor and former Facebook employee Chamath Palihapitiya would not sell Facebook over data flap; 26/03/2018 – Android phone users have noticed that Facebook has saved a virtual trove of their personal call data for years:; 11/04/2018 – LBC Breaking: Facebook co-founder Mark Zuckerberg’s told US lawmakers his own personal data has been sold to “malicious third; 19/04/2018 – Facebook’s facial recognition tech could fall foul of new EU data rules, a top watchdog says; 04/04/2018 – Rep. Cardenas: CONGRESSMAN TONY CARDENAS WANTS PRIVACY ANSWERS FROM FACEBOOK; 14/05/2018 – Facebook CEO Mark Zuckerberg turns 34 today; 23/03/2018 – Facebook dropped from Australian Ethical ETF after data breach; 24/04/2018 – WHATSAPP SAYS IT IS NOT CURRENTLY SHARING ACCOUNT INFORMATION TO IMPROVE USERS’ PRODUCT & ADS EXPERIENCE ON FACEBOOK; 11/04/2018 – Facebook CEO Mark Zuckerberg appeared in front of lawmakers from the Senate Judiciary and Commerce committees Tuesday; 18/03/2018 – U.S. Republican lawmakers concerned by Facebook data leak

More notable recent Facebook, Inc. (NASDAQ:FB) news were published by: Nasdaq.com which released: “Facebook (FB) to Terminate P2P Services in UK and France – Nasdaq” on April 17, 2019, also Nasdaq.com with their article: “Even Up 45%, FB Stock Is Worth a Like Ahead of NFLX Earnings – Nasdaq” published on April 16, 2019, Nasdaq.com published: “Facebook (FB) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release – Nasdaq” on April 17, 2019. More interesting news about Facebook, Inc. (NASDAQ:FB) were released by: Nasdaq.com and their article: “Buy Facebook (FB) Stock on Instagram ‘Checkout’ E-Commerce Innovation? – Nasdaq” published on April 02, 2019 as well as Nasdaq.com‘s news article titled: “Facebook (FB) to Briefly Block Foreign Ad Buyers in Australia – Nasdaq” with publication date: April 05, 2019.

Investors sentiment decreased to 0.71 in Q4 2018. Its down 0.42, from 1.13 in 2018Q3. It dropped, as 143 investors sold FB shares while 740 reduced holdings. 166 funds opened positions while 465 raised stakes. 1.73 billion shares or 7.30% more from 1.61 billion shares in 2018Q3 were reported. Wilbanks Smith Thomas Asset Mngmt Ltd Limited Liability Company has invested 0.08% in Facebook, Inc. (NASDAQ:FB). Ruggie Group has invested 0.03% in Facebook, Inc. (NASDAQ:FB). Ccm Invest Advisers Ltd Company has invested 0.28% in Facebook, Inc. (NASDAQ:FB). Bainco reported 0.88% stake. Somerville Kurt F reported 0.07% stake. 258,762 were accumulated by Tiverton Asset Llc. Cim Invest Mangement Inc reported 14,082 shares. Blb&B Ltd holds 0.43% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 23,816 shares. Stelac Advisory Services Limited Liability Company, a New York-based fund reported 2,585 shares. Tpg Grp (Sbs) Advisors has 1.05% invested in Facebook, Inc. (NASDAQ:FB). Camarda Fin Advsr Ltd Liability Com stated it has 0.07% in Facebook, Inc. (NASDAQ:FB). Tributary Capital Management Ltd Liability Co stated it has 0.07% in Facebook, Inc. (NASDAQ:FB). Green Square Capital Lc has 30,172 shares. Lone Pine Capital Limited Liability Company holds 5.92% or 6.67 million shares. Northeast holds 2.54% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 201,595 shares.

Since October 23, 2018, it had 0 insider purchases, and 25 insider sales for $66.62 million activity. On Thursday, November 1 FISCHER DAVID B. sold $236,371 worth of Facebook, Inc. (NASDAQ:FB) or 1,560 shares. $116,250 worth of Facebook, Inc. (NASDAQ:FB) shares were sold by Stretch Colin. Another trade for 2,112 shares valued at $290,400 was sold by Taylor Susan J.S.. Shares for $2.39 million were sold by Cox Christopher K. Wehner David M. also sold $671,777 worth of Facebook, Inc. (NASDAQ:FB) shares. Sandberg Sheryl sold $7.97 million worth of stock or 55,000 shares. $5.45 million worth of stock was sold by Schroepfer Michael Todd on Tuesday, November 13.

Among 18 analysts covering Facebook (NASDAQ:FB), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. Facebook had 41 analyst reports since October 24, 2018 according to SRatingsIntel. Nomura maintained the stock with “Neutral” rating in Wednesday, October 31 report. Rosenblatt maintained Facebook, Inc. (NASDAQ:FB) on Tuesday, March 5 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Thursday, March 7. As per Wednesday, October 31, the company rating was maintained by BMO Capital Markets. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, February 20. The firm has “Overweight” rating by Morgan Stanley given on Thursday, January 31. The stock has “Buy” rating by Mizuho on Monday, March 18. Nomura maintained it with “Neutral” rating and $172 target in Thursday, January 31 report. The company was maintained on Wednesday, October 31 by Deutsche Bank. Canaccord Genuity maintained Facebook, Inc. (NASDAQ:FB) on Wednesday, October 31 with “Buy” rating.

Calamos Wealth Management Llc increased Ishares S&P 500 Value Etf (IVE) stake by 163,356 shares to 175,136 valued at $17.71M in 2018Q4. It also upped Cboe Global Markets Inc (NASDAQ:CBOE) stake by 35,883 shares and now owns 38,941 shares. Union Pacific Corp (NYSE:UNP) was raised too.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on April, 24. They expect $1.63 earnings per share, down 3.55% or $0.06 from last year’s $1.69 per share. FB’s profit will be $4.65B for 27.40 P/E if the $1.63 EPS becomes a reality. After $2.38 actual earnings per share reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts -31.51% negative EPS growth.

Bvf Inc Il holds 2.69% of its portfolio in Infinity Pharmaceuticals, Inc. for 17.43 million shares. Anson Funds Management Lp owns 293,427 shares or 0.2% of their US portfolio. Moreover, Platinum Investment Management Ltd has 0.05% invested in the company for 1.14 million shares. The Hong Kong-based Fosun International Ltd has invested 0.03% in the stock. Clear Harbor Asset Management Llc, a New York-based fund reported 74,880 shares.

The stock decreased 3.68% or $0.06 during the last trading session, reaching $1.57. About 87,825 shares traded. Infinity Pharmaceuticals, Inc. (INFI) has declined 16.67% since April 17, 2018 and is downtrending. It has underperformed by 21.04% the S&P500. Some Historical INFI News: 13/03/2018 – FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA┬« (pembrolizumab) for; 06/03/2018 – BIOLINERX SEES PHASE 2A BL-8040, KEYTRUDA COMBO RESULTS 2H `18; 10/04/2018 – The University of Texas MD Anderson Cancer Center and Nanobiotix Have an Agreement to Run lmmunotherapeutic Pre-Clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab; 16/04/2018 – Bristol-Myers: In Phase 3 CheckMate -214 Clinical Trial, Opdivo + Yervoy Combination Demonstrated a Significant and Unprecedented Increase in Overall Survival; 06/03/2018 – Bristol-Myers: Opdivo Dosing Now Includes 480 Mg Infused Every Four Weeks for Majority of Approved Indications; 23/04/2018 – European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA┬« (pembrolizumab) in Combination with Pemetrexed; 06/03/2018 – Bristol-Myers Opdivo Indicated for Metastatic Melanoma, Other Cancers; 26/03/2018 – Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma; 03/05/2018 – European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination; 13/03/2018 – MERCK & CO INC – SBLA FOR KEYTRUDA IS BASED IN PART ON DATA FROM PHASE 2 KEYNOTE-158 TRIAL

Since January 1, 0001, it had 4 buys, and 0 insider sales for $3.57 million activity.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart